Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients

Part of paid clinical trials in Gainesville, Florida.

Sponsor: University of Florida
Study ID: NCT07766980
Status: Recruiting

Apply to this trial

Conditions

DMD
Duchenne Disease
Duchenne Muscular Dystrophy
Muscular Dystrophy
Muscular Dystrophy in Children

Eligibility Criteria

Sex: MALE
Age: 6 Years - N/A
Healthy Volunteers: Not accepted

Interventions

VM100 Nutritional Supplement — DIETARY_SUPPLEMENT
VM100 is an investigational dietary supplement formulated specifically for individuals with Duchenne muscular dystrophy. It contains ten naturally derived ingredients formulated using a proprietary technology to enhance bioavailability. The supplement is intended to support mitochondrial function, reduce inflammation and oxidative stress, improve cognitive function and mood, and promote overall quality of life. Participants will self-administer the supplement orally twice daily during the intervention period.

Study Details

This pilot study will investigate the potential efficacy of VM100, a nutritional supplement specifically formulated for patients with DMD, on quality of life and physical symptoms. Twenty patients (aged 8 an over) will be enrolled to undergo a 10-week placebo-controlled intervention with VM100. Outcomes will include validated questionnaires and qualitative interview to assess impact on mental, cognitive and mood related measures, as well as endurance and fatigue).

Key Dates

First listed: Aug 17, 2026
Start date: Jul 27, 2026
Status verified: Oct 2025
Primary completion: Dec 31, 2028
Completion: Dec 31, 2028

Study Design

Enrollment: 20 participants (estimated)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: VM100 Nutritional Supplement
Participants will receive the VM100 nutritional supplement orally twice daily for 10 weeks, consisting of 6 weeks of supplementation, followed by a 2-week washout period without supplementation, and a final 2 weeks of supplementation.